Methods. Among 104 VSs treated by GKS at the Chiba Cardiovascular Center between 1998 and 2004, 87 consecutively treated unilateral VSs observed on follow-up MR imaging for at least 5 years were analyzed. These lesions were harbored by 31 men and 56 women, with a mean age of 58.6 years (range 29-80 years). The Gd-enhanced volume of each lesion was measured serially every 3 months during the 1st year and every 6 months thereafter using GammaPlan or SurgiPlan. The frequency and degree of volume shrinkage were documented and possible prognostic factors were analyzed.
R ecently, GKS for small VSs became accepted as an efficacious treatment that produces high tumor control rates with extremely low incidences of severe complications. 6, 7, [12] [13] [14] [15] [16] However, occasionally we observe an initial enlargement of these lesion accompanied by central low intensity on neuroimaging studies within 1 year after treatment; this is known as "temporary enlargement,"
10 "tumor expansion," 4,13 "transient swelling," 18 or "transient expansion." 3, 9 Thereafter, tumor volume gradually decreases over a 1-year period. In this study, we focused on tumor volume changes, prospectively analyzing degrees of volume reduction in VSs after GKS.
Methods

Patient Population
Among 104 patients with unilateral VSs treated by GKS at the Chiba Cardiovascular Center between 1998 and 2004, 87 patients (84%) participated in follow-up with MR imaging for at least 5 years; these cases are the focus of this analysis. Seventeen other patients were excluded from this study because we only obtained long-term follow-up images and were unable to evaluate tumor volume changes, especially during the 1st year after GKS. Patient characteristics are shown in Table 1 . There were 31 men and 56 women, with a mean age of 58.6 years (median 59 years, range 29-80 years). Twenty-seven patients (31%) had undergone resection before GKS.
Tumor shrinkage of vestibular schwannomas after Gamma Knife surgery: results after more than 5 years of follow-up After each patient received local anesthesia with adequate sedation, GKS started with placement of the patient's head in a rigid-fixation Leksell G stereotactic frame (Elekta AB). Treatment planning was performed using the Leksell GammaPlan by 1 neurosurgeon (T.S.) in all cases. For dose planning, we always use contrastenhanced T1-weighted gradient-echo axial MR sequences (TR 45 msec, TE 3.5 msec, flip angle 30°, field of view 260 mm, slice thickness 2 mm, interslice gap 0 mm, and matrix 400 × 382) and continuous interference steadystate sequences and CT scanning. Seventy-five patients were treated using the Gamma Knife model B and 12 using the model C (Elekta AB). We used the multiple isocenter technique and set the optimal peripheral dose at 12 Gy directed to the 50% isodose line, changing this value according to individual situations such as tumor size.
Follow-up neuroimaging included contrast-enhanced T1-weighted gradient-echo MR imaging sequences, which were the same as those used for dose planning. For each lesion, the Gd-enhanced volume was measured serially every 3 months during the 1st year and every 6 months thereafter, using noninvasive volumetric software (GammaPlan or SurgiPlan, Elekta AB). The volume measurements were made by 2 neurosurgeons (T.S. and O.N.). Error was estimated to be < 5%, as verified by phantom studies at another site. 1, 2 We found the margin of error using this method to be ± 5% for lesions in our phantom studies (data not shown). Significant tumor expansion was defined as > 10% enlargement. We defined transient expansion as ≥ 10% increase in tumor volume after radiosurgery, followed later by tumor shrinkage. The frequency of transient expansion and the degree of volume changes were documented. To analyze prognostic factors, we assessed the following dichotomized variables: patient age (< 60 vs ≥ 60 years), patient sex (male vs female), previous surgery (yes vs no), tumor volume (< 2 vs ≥ 2 cm 3 ), the Paddick conformity index 11 (< 0.8 vs ≥ 0.8), and MR imaging findings (homogeneous enhancement vs heterogeneous enhancement). We defined homogeneous enhancement as the lack of a low-intensity area in the tumor on Gd-enhanced MR images before GKS (Fig. 1) . Factors affecting tumor shrinkage were evaluated using a logistic regression model. A probability value of < 0.05 was defined as statistically significant. Neurological deterioration involving trigeminal and facial nerve functions was examined along with follow-up neuroimages by 1 neurosurgeon (T.S.). Trigeminal neuropathy was defined as any facial dysesthesia within the ipsilateral trigeminal nerve distribution. Facial neuropathy was defined as any deterioration in House-Brackmann facial nerve grade.
Results
Radiosurgical Techniques
The radiosurgical parameters are shown in Table 2 . The mean tumor volume at GKS was 2.5 cm 3 (median 1.9 cm 3 , range 0.1-13.2 cm 3 ). The mean peripheral dose was 12 Gy (median 12 Gy, range 10.5-13 Gy). The isodose line for the tumor margin varied from 50% to 67% (mean 52.2%, median 50%). The peripheral dose coincided with 12 Gy directed to the 50% isodose line in 76 cases. Isocenter numbers ranged from 4 to 39 (mean 16, median 15 isocenters), and the mean Paddick conformity index was 0.8 (median 0.81, range 0.43-0.93). Twenty-nine tumors (33%) displayed homogeneous enhancement. The mean follow-up period was 7.5 years (median 7.1 years, range 5.0-11.1 years).
Changes in Tumor Volume
In this study, 67 tumors (77%) exhibited transient expansion (≥ 10% increase followed later by tumor shrinkage). The maximum tumor expansion rates are shown in Fig. 2 . The volume increase was < 10% (no significant increase) in 20 tumors, 10%-30% in 19, 31%-50% in 19, 51%-100% in 15, and > 100% in 14 tumors (mean 58%, range 0%-613%). Changes in volume ratios are shown in Fig. 3 . Peak tumor expansion was most frequently observed at 8.6 months after GKS. One-half of the 87 tumors regressed to their initial size within 1.5 years. The mean volume reduction was 31% at 5 years after GKS. Nine tumors (10.3%) remained larger than they had been before GKS as long as 5 years after treatment.
Tumor volume changes stratified by patient age and sex, previous surgery, tumor volume, conformity index, and MR imaging findings are presented in Fig. 4 . A homogeneously enhancing tumor seems to be the greatest risk factor for lack of tumor shrinkage. There was a statistically significant difference between homogeneously and heterogeneously enhanced VSs.
We divided volume changes into 3 categories. 1) Transient expansion followed by progressive tumor shrinkage occurred in 60 patients. Maximal transient expansion was generally seen at 6-12 months, although in 16 patients prolonged tumor expansion was documented for up to 24 months before shrinkage began. 2) Direct tumor shrinkage (no transient expansion) was seen in 20 patients. 3) Repeated increases in tumor volume (that is transient expansions) occurred > 2 years after GKS in 7 patients. One patient in this latter group underwent microsurgery 6 years after GKS because of intractable trigeminal neuralgia. Histological examination showed typical schwannoma with partial myxoid degeneration. Changes in volume ratios are shown in Fig. 5 .
Functional Outcomes
Facial dysesthesia was triggered by a tumor pushing against the trigeminal nerve. All MR images obtained in the 17 patients with trigeminal neuropathy showed tumor tissue abutting the trigeminal nerve before or after treatment, and in 7 patients, this tissue subsequently separated from the trigeminal nerve as the tumor shrank. Improvement in trigeminal neuropathy was seen a few months after the tumor had moved away from the trigeminal nerve. Fourteen patients experienced facial paresis as tumor volume increased. The most common problem of this type was facial spasm (10 patients [71%]). In this study, all patients with facial palsy experienced a rapid and full recovery to their pre-GKS status as the tumor shrank.
Discussion
We found that transient tumor expansion, with peak expansion usually observed at 6-12 months, represented a mean increase of nearly 50% in volume compared with initial (pre-GKS) tumor volume. Incidences of transient tumor expansion reportedly occur in between 39% and 62% of patients based on 3D measurements obtained using the GammaPlan. 16, 18 In this study, significant transient tumor expansion (≥ 10% increase) was documented in 77% of patients. This difference in percentages of patients with transient tumor expansion is attributable to differing observation periods and cutoff values. After a period of expansion, most tumors shrink. We found a volume reduction of 31% at 5 years after GKS. Yu et al. 18 reported a 46.8% shrinkage rate in 92% of their VS cases 30 months after GKS, and Wowra et al. 16 reported a 35% shrinkage rate after 4 years. These findings are similar to our own. We believe that taking 3D measurements should be the standard method of documenting volume changes in VS, because 2D measurements are not suitable for detecting small changes in volume. For example, a 10% increase in diameter is equivalent to a 33% volume expansion.
In our series, 7 tumors in 7 patients repeatedly enlarged after the initial transient expansion. In 5 of the 7 tumors, only the cystic components of the lesions enlarged, whereas the solid components diminished in size. In the other 2 tumors, expansion of an intratumoral lowintensity area was observed on MR images. Although we did not seek to clarify the mechanism of repeated tumor expansion in this study, several authors have suggested increased tumor size after GKS is caused by radiation-induced tumor necrosis, 14 chronic intratumoral bleeding resulting from delayed radiation injury, 5 minor hemorrhage from a cystic component, 10 and/or a biological response to radiation.
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Our analyses seem to indicate that homogeneous tumor enhancement on MR images is associated with a risk of insufficient tumor shrinkage. Homogeneous enhancement was identified as an independent factor in the multivariate analysis (p = 0.0022). Moon et al. 8 wrote about 2 types of tissue found in these tumors.
In VS, 2 tissue types can be distinguished. One, Antoni Type A, has a compact texture with interwoven bundles of long bipolar spindle cells that have a tendency to palisade. The other, Antoni Type B, is characterized by its loose texture and is composed of uniform, small, somewhat satellite cells. It is known that the cystic portion of VS is located in the Antoni Type B area, which is softer than the Type A area.
Yang et al. 17 reported that the tumor control rate of cystic VSs is higher than that of solid VSs after GKS. We suggest that there are biological differences between VSs that display homogeneous enhancement and those that exhibit heterogeneous enhancement. Additional followup of patients harboring VSs is anticipated to provide more insights into the risk factors associated with volume changes after GKS.
Conclusions
Most VSs display shrinkage at 5 years after GKS. In this series, the mean volume reduction was 31%. Our findings indicate that careful serial follow-up is essential for cases in which the tumor displays homogeneous enhancement on MR images and for cases in which the tumor repeatedly expands in size after GKS.
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